Sichenzia Ross Ference Carmel LLP represents BriaCell Therapeutics in $8.5 Million Offering

Press Release – New York, NY – September 12, 2024 – Sichenzia Ross Ference Carmel LLP announced today that it represented BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, in its registered offering of 12,325,000 common shares. Each common share was sold at an offering price of $0.69 per share for gross proceeds of approximately $8.5 million.  

The SRFC team was led by partners Gregory Sichenzia and Avital Perlman, and associates Christian Lichtenberger and Benasz Hansotia.